Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone

Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone in Female Patients Before Anesthesia Induction

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04396587

Enrollment

Registered

2020-05-20

Start date

2020-05-20

Completion date

2023-06-01

Last updated

2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use

Brief summary

This study aimed to investigate Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone in female patients. Methods: A total of 60 patients were randomly divided into 4 groups, with 20 patients in each group. Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) ,saline(10ml)was administered before anesthesia induction. Bispectral Index (BIS), Respiratory rate(RR), other non-analgesic effects at Tb (entering room), T0 (drug administration), T1 (2min), T2 (4min), T3(6min), T4(8min), T5(10min), T6(20min) were recorded.

Interventions

DRUGSufentanil

Sufentanil(0.1μg/kg) was administered before anesthesia induction.

DRUGHydromorphone

Hydromorphone(20μg/kg)was administered before anesthesia induction.

DRUGOxycodone

Oxycodone(60μg/kg) was administered before anesthesia induction.

DRUGnormal Saline

normal saline 10ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists GradeⅠ-II; * Patients undergo low-risk elective surgery for benign diseases (including laparoscopic ovarian cyst removal, laparoscopic tubal ligation, laparoscopic tubal drainage, breast operation, thyroid operation, etc) ; * Aged 18-45 years; * Body Mass Index 18-25kg/m2, weight 40-65 kilograms; * Agreed to participate in the research

Exclusion criteria

* Difficult airway; * upper respiratory tract infection within 2 weeks; * history of allergy or long-term use of propofol and opioids; * self-rating anxiety scale before operation indicates anxiety; * pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame	Description
Respiratory rate	20 minutes after administration	Number of breaths per minute
Bispectral Index	20 minutes after administration	bispectral index(BIS): assessing the sedation, placed on the patient's forehead, BIS values 0-100, and the higher score means patients are more conscious
dizziness	20 minutes after administration	a temporary feeling that your sense of balance is not good and that you may fall down

Secondary

Measure	Time frame	Description
itch	20 minutes after administration	itch
sweating	20 minutes after administration	sweating
nausea or vomiting	20 minutes after administration	nausea or vomiting
drowsiness	20 minutes after administration	drowsiness

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026